Skip to main content

Table 4 Pooled analytical performances of the Ion AmpliSeq TB Research Panel for detecting of drug resistances

From: Application of next-generation sequencing to detect variants of drug-resistant Mycobacterium tuberculosis: genotype–phenotype correlation

Drug

Pooled sensitivity (%) (95% CI)

Pooled specificity (%) (95% CI)

Prevalence of drug resistance [10] (%)

PPV (%) (95% CI)

NPV (%) (95% CI)

INH

91.3 (82.0–96.7)

100.0 (86.3–100.0)

15.5

100.0 (100.0–100.0)

98.4 (96.7–99.3)

RFP

98.0 (89.1–99.9)

98.0 (89.6–100.0)

9.3

83.7 (42.4–97.3)

99.8 (98.5–100.0)

EMB

96.7 (87.8–99.9)

90.0 (80.5–95.9)

6.7

41.0 (25.5–58.4)

99.7 (98.2–100.0)

PZA

65.0 (40.8–84.6)

96.3 (89.4–99.2)

4.3

43.8 (19.7–71.2)

98.4 (97.1–99.1)

SM

62.1 (42.3–79.3)

98.6 (92.4–100.0)

5.4

71.6 (26.0–94.7)

97.9 (96.6–98.6)

AMK, KM

0.0 (0.0–70.8)

100.0 (96.3–100.0)

2.2

N/A

97.8 (97.8–97.8)

FQ

66.7 (34.9–90.1)

100.0 (95.9–100.0)

2.9

100.0 (100.0–100.0)

99.0 (97.8–99.6)

  1. CI confidence interval, PPV positive predictive value, NPV negative predictive value, INH isoniazid, RFP rifampin, EMB ethambutol, PZA pyrazinamide, SM streptomycin, AMK amikacin, KM kanamycin, FQ fluoroquinolones, N/A not applicable